The estimated Net Worth of Oren Gilad is at least $1.05 Million dollars as of 13 March 2024. Dr Gilad owns over 2,000 units of Aprea Therapeutics stock worth over $1,045,759 and over the last 2 years he sold APRE stock worth over $0. In addition, he makes $0 as Co-Founder und Pres & Director at Aprea Therapeutics.
Dr has made over 1 trades of the Aprea Therapeutics stock since 2024, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of APRE stock worth $14,580 on 13 March 2024.
The largest trade he's ever made was buying 2,000 units of Aprea Therapeutics stock on 13 March 2024 worth over $14,580. On average, Dr trades about 500 units every 0 days since 2022. As of 13 March 2024 he still owns at least 324,770 units of Aprea Therapeutics stock.
You can see the complete history of Dr Gilad stock trades at the bottom of the page.
Dr. Oren Gilad Ph.D. is the Co-Founder, Pres & Director at Aprea Therapeutics.
Dr D is 53, he's been the Co-Founder und Pres & Director of Aprea Therapeutics since . There are 11 older and 5 younger executives at Aprea Therapeutics. The oldest executive at Aprea Therapeutics, Inc. is Guido Magni, 67, who is the Independent Director.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... und John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: